A new treatment does not reach patients simply because clinical trials show that it works. After clinical development and regulatory review comes another crucial question: »Will healthcare systems pay for it, and for whom?
In 2026, the UK's National Institute for Health and Care Excellence moved forward with its technology appraisal of topical tapinarof for atopic dermatitis in people aged two years and older. The project reached its invitation-to-participate stage on 30 July 2026 following the earlier scoping process.
This is an important part of health technology assessment. NICE technology appraisals examine more than whether a medicine improves symptoms. They consider where the treatment belongs within existing care, what alternative therapies are available, how much benefit it provides and whether its cost represents reasonable value for the publicly funded National Health Service. That process is especially relevant in atopic dermatitis because the treatment landscape has expanded rapidly.
Tapinarof is a non-steroidal topical therapy. Topical treatments remain central to atopic dermatitis management even in an era of biologics and JAK inhibitors, because many people have disease that can be managed primarily through treatments applied directly to the skin. Others use topical medicines alongside systemic treatment. Additional non-steroidal options are therefore important.
Topical corticosteroids are highly effective and remain a cornerstone of treatment, but patients may require repeated courses over long periods and treatment needs differ depending on body area, age and disease severity.
Tapinarof acts through the aryl hydrocarbon receptor, or AhR, a pathway involved in skin-barrier function and immune regulation. Its different mechanism could provide another option within increasingly personalised topical care. NICE's proposed appraisal covers patients from two years of age, meaning its eventual assessment could be relevant to both children and adults.
However, inclusion in a NICE appraisal programme is not the same as a recommendation. NICE still needs to consider the relevant clinical and economic evidence before making recommendations. That distinction matters. A regulatory approval answers whether a medicine can be marketed. An HTA decision addresses whether and under what circumstances a healthcare system should routinely provide it.
For patients, that second decision can determine whether innovation exists only on paper or is actually available in the clinic. The tapinarof appraisal is therefore one to follow. It represents another step in the long journey from laboratory science to clinical trial, regulatory review, reimbursement and everyday patient access.